Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 20/20 | 0.85 |
| ▸ | CDC7 | O00311 | 1/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | PAK4 | O96013 | 1/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.65 |
| ▸ | PRKCB | P05771 | 1/20 | 0.65 |
| ▸ | INSR | P06213 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | KIT | P10721 | 1/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.65 |
| ▸ | PRKACA | P17612 | 1/20 | 0.65 |
| ▸ | FLT4 | P35916 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | JAK3 | P52333 | 1/20 | 0.65 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.65 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.65 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881690 | 0.92 | AURKA (1.00) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL3882192 | 0.92 | AURKA (1.00) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL3885716 | 0.84 | AURKA (0.84) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL3881091 | 0.84 | AURKA (0.86) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL3880422 | 0.83 | AURKA (1.00) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL3891045 | 0.83 | AURKA (1.00) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL3892391 | 0.83 | AURKA (1.00) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL3878843 | 0.82 | AURKA (0.75) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL3888941 | 0.82 | AURKA (0.85) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL3879467 | 0.82 | AURKA (0.71) | AURKACDC7CHEK1JAK2PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485661-B2 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-02-03 | — | — | US | claimed |
| EP-1534716-B1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-04-23 | — | — | EP | claimed |
| US-7485661-B2 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-02-03 | — | — | US | disclosed |
| EP-1534716-B1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-04-23 | — | — | EP | disclosed |
| US-20060160874-A1 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2006-07-20 | — | — | US | disclosed |
| EP-1534716-A1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004007504-A1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160874-A1 | Heterobicyclic pyrazole derivatives as kinase inhibitors | MAP2K2, MAP3K15, MAP3K5 | AURKA 239/4885CDC7 278/4885CHEK1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.